Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review

Dorota Lorenz; Rafał Pawliczak

doi:10.5114/pja.2022.114394

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2022
vol. 9

Send email

Copy url:

abstract:

Review paper

Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review

Dorota Lorenz

¹

,

Rafał Pawliczak

¹

Department of Immunopathology, Medical Faculty, Medical Univesity of Lodz, Lodz, Poland

Alergologia Polska – Polish Journal of Allergology 2022; 9, 1: 33–40

DOI: https://doi.org/10.5114/pja.2022.114394

Online publish date: 2022/03/09

View full text Get citation

PlumX metrics:

COVID-19 is an infectious disease that is caused by coronavirus SARS-CoV-2. As the time passed it became clear that, aside from the vaccines, other efficient methods of fighting the disease are urgently needed. Among the whole list of medicines used to treat COVID-19, those which are administered orally have a great advantage. The aim of this paper is to present the current knowledge about the recently investigated oral medications for COVID-19. The authors present molnupiravir (Lagevrio), baricitinib (Olumiant) and ritonavir + PF-07321332 (Paxlovid). All of these drugs have been registered recently or are waiting for authorization by EMA or FDA. During the study, the authors learned that huge progress was made, nevertheless, more studies are needed, especially in the field of side effects and drug-drug interactions of the considered substances.

keywords:

Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review

Dorota Lorenz 1 , Rafał Pawliczak 1

COVID-19, drugs, oral, pills, molnupiravir, beta-d-N4-hydroxycitidine, eidd-2801, mk4482, baricitinib, ritonavir, PF-07321332, nirmatrelvir

Dorota Lorenz

¹

,

Rafał Pawliczak

¹